J. Christopher Naftzger - Feb 14, 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: General Counsel and CCO
Signature: /s/ David C. Hastings as attorney-in-fact for J. Christopher Naftzger
Stock symbol: ABUS
Transactions as of: Feb 14, 2025
Transactions value $: $0
Form type: 4
Date filed: 2/19/2025, 06:25 PM
Previous filing: Feb 5, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABUS	Common Shares	Award	$0	+54.3K	+62.96%	$0.00	141K	Feb 14, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+220K		$0.00	220K	Feb 14, 2025	Common Shares	220K	$3.29	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
F2	Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F3	This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.